181 related articles for article (PubMed ID: 17522103)
21. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
[TBL] [Abstract][Full Text] [Related]
22. [A randomized controlled trial with methotrexate (MTX), 5-fluorouracil (5-FU) and pirarubicin (THP) vs 5-FU alone in advanced or recurrent gastric carcinoma. Tokai Hokuriku THP Study Group].
Yamamura Y; Miyazaki I; Ogawa M; Yonemura Y; Tanemura H; Kito T; Hamajima N; Saji S; Kosaka T
Gan To Kagaku Ryoho; 1998 Aug; 25(10):1543-8. PubMed ID: 9725047
[TBL] [Abstract][Full Text] [Related]
23. [Low-dose FP therapy for advanced and recurrent gastric cancer].
Yamashita Y; Ohira M; Sowa M; Shirasaka T; Hirakawa K; Chung YS
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1548-53. PubMed ID: 10553411
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.
Hamaguchi T; Shirao K; Yamamichi N; Hyodo I; Koizumi W; Seki S; Imamura T; Honma H; Ohtsu A; Boku N; Mukai T; Yamamoto S; Fukuda H; Yoshida S;
Jpn J Clin Oncol; 2008 Jun; 38(6):432-7. PubMed ID: 18515821
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer.
Im CK; Jeung HC; Rha SY; Yoo NC; Noh SH; Roh JK; Chung HC
Cancer Chemother Pharmacol; 2008 Feb; 61(2):315-21. PubMed ID: 18026677
[TBL] [Abstract][Full Text] [Related]
26. Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study.
Yoshida M; Ohtsu A; Boku N; Miyata Y; Shirao K; Shimada Y; Hyodo I; Koizumi W; Kurihara M; Yoshida S; Yamamoto S
Jpn J Clin Oncol; 2004 Nov; 34(11):654-9. PubMed ID: 15613554
[TBL] [Abstract][Full Text] [Related]
27. Intermittent FLDP: 24-h infusion of 5-FU on days 1, 3 and 5 combined with low-dose cisplatin on days 1-5 for gastric cancer, and its pharmacologic and kinetic rationale.
Terashima M; Irinoda T; Kawamura H; Takagane A; Abe K; Oyama K; Fujiwara H; Saito K; Gotoh M; Shirasaka T
Cancer Chemother Pharmacol; 2003 Mar; 51(3):240-6. PubMed ID: 12655443
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy with CDDP and 5-fluorouracil for gastric cancer with serosal invasion.
Takiguchi N; Nunomura M; Koda K; Oda K; Suzuki H; Miyazaki M
Oncol Rep; 2003; 10(2):433-8. PubMed ID: 12579285
[TBL] [Abstract][Full Text] [Related]
29. [Therapeutic efficacy of intra-peritoneal infusion of cisplatin and continuous intravenous infusion of 5-fluorouracil in gastric cancer patients with peritoneal metastasis].
Terashima M; Takagane A; Oyama K; Abe K; Araya M; Yonezawa H; Irinoda T; Nakaya T; Shimooki O; Inaba T; Fujiwara H; Saito K
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1806-8. PubMed ID: 10560399
[TBL] [Abstract][Full Text] [Related]
30. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Gu Y; Shu Y; Xu Q
Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
[TBL] [Abstract][Full Text] [Related]
31. [Pathological evaluation of neoadjuvant chemotherapy with low-dose FP therapy for advanced gastric cancer].
Takano S; Oda K; Koda K; Seike K; Takiguchi N; Miyazaki M
Gan To Kagaku Ryoho; 2007 Apr; 34(4):555-8. PubMed ID: 17431341
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial.
Kim YH; Yamaguchi K; Bang YJ; Takiuchi H; Kang WK; Sato A; Kang YK; Sakamoto J; Abe C; Sakata Y
Jpn J Clin Oncol; 2007 Jul; 37(7):501-8. PubMed ID: 17673470
[TBL] [Abstract][Full Text] [Related]
33. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients.
Sakaeda T; Yamamori M; Kuwahara A; Hiroe S; Nakamura T; Okumura K; Okuno T; Miki I; Chayahara N; Okamura N; Tamura T
Ther Drug Monit; 2008 Aug; 30(4):497-503. PubMed ID: 18641541
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy.
Kim KH; Kwon HC; Oh SY; Kim SH; Lee S; Kwon KA; Jang JS; Kim MC; Kim SJ; Kim HJ
Biomarkers; 2011 Feb; 16(1):74-82. PubMed ID: 21133646
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Di Costanzo F; Gasperoni S; Manzione L; Bisagni G; Labianca R; Bravi S; Cortesi E; Carlini P; Bracci R; Tomao S; Messerini L; Arcangeli A; Torri V; Bilancia D; Floriani I; Tonato M; ; Dinota A; Strafiuso G; Corgna E; Porrozzi S; Boni C; Rondini E; Giunta A; Monzio Compagnoni B; Biagioni F; Cesari M; Fornarini G; Nelli F; Carboni M; Cognetti F; Enzo MR; Piga A; Romiti A; Olivetti A; Masoni L; De Stefanis M; Dalla Mola A; Camera S; Recchia F; De Filippis S; Scipioni L; Zironi S; Luppi G; Italia M; Banducci S; Pisani Leretti A; Massidda B; Ionta MT; Nicolosi A; Canaletti R; Biscottini B; Grigniani F; Di Costanzo F; Rovei R; Croce E; Carroccio R; Gilli G; Cavalli C; Olgiati A; Pandolfi U; Rossetti R; Natalini G; Foa P; Oldani S; Bruno L; Cascinu S; Catalano G; Catalano V; Lungarotti F; Farris A; Sarobba MG; Trignano M; Muscogiuri A; Francavilla F; Figoli F; Leoni M; Papiani G; Orselli G; Antimi M; Bellini V; Cabassi A; Contu A; Pazzola A; Frignano M; Lastraioli E; Saggese M; Bianchini D; Antonuzzo L; Mela M; Camisa R
J Natl Cancer Inst; 2008 Mar; 100(6):388-98. PubMed ID: 18334706
[TBL] [Abstract][Full Text] [Related]
37. [The third report from Sapporo Tsukisamu Hospital--chemotherapy for patients with advanced gastric cancer (peritoneal dissemination, peritonitis carcinomatosa)].
Yamamitsu S; Kimura H; Yamada Y; Inui N; Hiyama S; Hirata K; Kimura Y; Yamaguchi K; Shirasaka T
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1405-11. PubMed ID: 17876138
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).
Ohtsu A; Shimada Y; Shirao K; Boku N; Hyodo I; Saito H; Yamamichi N; Miyata Y; Ikeda N; Yamamoto S; Fukuda H; Yoshida S;
J Clin Oncol; 2003 Jan; 21(1):54-9. PubMed ID: 12506170
[TBL] [Abstract][Full Text] [Related]
39. Combination chemotherapy with 5-fluorouracil, cisplatin and paclitaxel for pretreated patients with advanced gastric cancer.
Yamaguchi K; Nakagawa S; Yabusaki H; Nashimoto A
Anticancer Res; 2007; 27(5B):3535-9. PubMed ID: 17972514
[TBL] [Abstract][Full Text] [Related]
40. The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma.
Sencan O; Buyukcelik A; Yalcin B; Boruban MC; Akbulut H; Demirkazik A; Senler FC; Onur H; Icli F
Eur J Cancer Care (Engl); 2008 Jan; 17(1):26-32. PubMed ID: 18181888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
